Komori
Mitsubishi Chemical Group (4188) · FactFirst-half revenue growth, core profit growth and operating profit growth, with lower profit attributable to owners of the parent

Achieved operating profit target and record-high profit

First written in FY2016. 5 of 29 entries say "Advanced", first in FY2018. Latest entry: FY2027-H1.

29entries
11years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2016OtherFY2019 – FY2026-H12016: 120162017: 020172018: 120182019: 120192020: 320202021: 420212022: 420222023: 420232024: 320242025: 220252026: 62026
Same theme, other companies
Record-high Revenue and ProfitA theme 153 companies write about · 0 as a headwind · 166 as a tailwind

The whole theme swung hardest in 2020: 16 of 111 companies on the "Worse" side.

56 other companies' latest entry also says "Other".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 153 companies compared. The sentences above are computed from all 153.
Full recordFilings, disclosures and news, newest first
  1. FY2027-H1First-half revenue growth, core profit growth and operating profit growth, with lower profit attributable to owners of the parentAnnual report

    「Revenue was ¥2.0371 trillion, up ¥238.0 billion (13.2%) from the same period of the previous year. Core operating profit was ¥202.8 billion, up ¥76.7 billion (60.9%); operating profit was ¥199.7 billion, up ¥113.2 billion (130.9%); interim profit before tax was ¥182.4 billion, up ¥113.7 billion (165.4%); and interim profit attributable to owners of the parent was ¥90.2 billion, down ¥19.9 billion (18.1%).」

    In FY2027-H1, revenue, core operating profit, operating profit and interim profit before tax increased year on year, while interim profit attributable to owners of the parent declined.
  2. 2026-06-30AdvancedGovernance

    「As management steadily advances bold reforms, including the selection and concentration of businesses, the Board of Directors has continued to undertake practical initiatives aimed at rebuilding an appropriate relationship of mutual trust between execution and supervision.」

    The effectiveness evaluation of the Board of Directors was specifically disclosed, including the third-party evaluation, identification of key issues, and initiatives to improve the Board’s role, discussions, and coordination with the Nomination Committee.
  3. FY2026Revenue decline, slight decrease in core profit and substantial decline in operating profitAnnual report

    「Revenue was ¥3.704 trillion, down ¥243.6 billion (6.2%). Core operating profit was ¥225.0 billion, down ¥3.8 billion (1.7%); operating profit was ¥30.1 billion, down ¥111.5 billion (78.8%); profit before tax was ¥700 million, down ¥98.5 billion (99.3%); and profit for the year attributable to owners of the parent was ¥11.8 billion, down ¥33.2 billion (73.7%).」

    On a continuing-operations basis, revenue and core operating profit declined, while operating profit, profit before tax and profit for the year attributable to owners of the parent fell substantially due to impairment losses, restructuring-related expenses and other factors.
  4. FY2026-H1First-half revenue decline, lower core profit and higher net profit from disposal gainsAnnual report

    「Revenue was ¥1.7991 trillion, down ¥210.7 billion, or 10.5%, from the previous corresponding period. Core operating profit was ¥126.1 billion, down ¥3.4 billion, or 2.6%, operating profit was ¥86.5 billion, down ¥21.1 billion, or 19.6%, and profit before tax was ¥68.7 billion, down ¥13.2 billion, or 16.1%. Profit for the interim period attributable to owners of the parent was ¥110.1 billion, up ¥69.2 billion, or 169.1%.」

    On a continuing-operations basis, excluding Mitsubishi Tanabe Pharma, which was classified as a discontinued operation, first-half revenue, core operating profit and operating profit declined. However, interim profit attributable to owners of the parent increased due to a gain on the transfer included in discontinued operations.
  5. FY2025Revenue growth, core profit growth and lower operating profitAnnual report

    「Revenue was ¥4.4074 trillion, up ¥20.2 billion, or 0.5%. On the earnings side, core operating profit was ¥298.4 billion, up ¥90.3 billion, or 43.4%; operating profit was ¥196.7 billion, down ¥65.1 billion, or 24.9%; profit before tax was ¥150.7 billion, down ¥89.8 billion, or 37.4%; and profit for the year attributable to owners of the parent was ¥45.0 billion, down ¥74.6 billion, or 62.4%.」

    In the current year, revenue and core operating profit increased, while operating profit, profit before tax and profit for the year attributable to owners of the parent declined due to non-recurring items, including impairment losses.
  6. FY2025-H1First-half revenue growth, core profit growth and lower operating profitAnnual report

    「Revenue was ¥2.2421 trillion, up ¥92.2 billion, or 4.3%, from the same period of the previous year. On the earnings side, core operating profit was ¥172.4 billion, up ¥52.8 billion, or 44.2%; operating profit was ¥136.7 billion, down ¥1.9 billion, or 1.4%; interim profit before tax was ¥106.1 billion, down ¥24.1 billion, or 18.5%; and interim profit attributable to owners of the parent was ¥40.9 billion, down ¥26.3 billion, or 39.1%.」

    In the current interim consolidated period, revenue and core operating profit increased, while operating profit, interim profit before tax and interim profit attributable to owners of the parent declined year on year.
  7. FY2024Full-year revenue decline, lower core profit and higher operating profitAnnual report

    「Revenue was ¥4.3872 trillion, down ¥247.3 billion from the previous consolidated fiscal year. On the earnings side, core operating profit was ¥208.1 billion, down ¥117.5 billion, operating profit was ¥261.8 billion, up ¥79.1 billion, profit before tax was ¥240.5 billion, up ¥72.5 billion, and profit for the year attributable to owners of the parent was ¥119.6 billion, up ¥23.2 billion.」

    In the current year, revenue and core operating profit declined, while operating profit, profit before tax and profit for the year attributable to owners of the parent increased, partly due to revenue recognition related to Gilenya.
  8. FY2024-Q3Nine-month revenue decline and core profit growthAnnual report

    「Revenue was ¥3.2451 trillion, down ¥161.1 billion year on year. On the earnings side, core operating profit was ¥183.9 billion, up ¥6.0 billion, operating profit was ¥212.5 billion, up ¥163.9 billion, quarterly profit before tax was ¥191.8 billion, up ¥152.6 billion, and quarterly profit attributable to owners of the parent was ¥103.9 billion, up ¥86.9 billion.」

    In the nine-month consolidated period, revenue declined, while core operating profit increased year on year and operating profit, profit before tax and quarterly profit attributable to owners of the parent increased substantially.
  9. FY2024-Q2First-half revenue decline and lower core profitAnnual report

    「Revenue was ¥2.1499 trillion, a decrease of ¥119.9 billion year on year. Core operating profit was ¥119.6 billion, down ¥3.0 billion, operating profit was ¥138.6 billion, up ¥20.2 billion, profit before tax was ¥130.2 billion, up ¥8.2 billion, and profit for the quarter attributable to owners of the parent was ¥67.2 billion, down ¥6.7 billion.」

    In the six months ended 30 September 2023, revenue and core operating profit declined year on year, while operating profit and quarterly profit before tax increased and quarterly profit attributable to owners of the parent declined.
  10. FY2024-Q1Quarterly revenue decline and lower core profitAnnual report

    「Revenue was ¥1.0612 trillion, a decrease of ¥45.3 billion year on year. Core operating profit was ¥50.8 billion, down ¥21.3 billion, operating profit was ¥69.7 billion, up ¥1.7 billion, profit before tax was ¥68.8 billion, down ¥6.3 billion, and profit for the quarter attributable to owners of the parent was ¥42.5 billion, down ¥2.4 billion.」

    In the first quarter of FY2024, revenue, core operating profit, quarterly profit before tax and quarterly profit attributable to owners of the parent declined year on year, while operating profit increased.
  11. FY2023Full-year revenue growth, core profit growth and lower operating profitAnnual report

    「Revenue was ¥4.6345 trillion, an increase of ¥657.6 billion from the previous consolidated fiscal year. Core operating profit was ¥325.6 billion, up ¥53.3 billion. Operating profit was ¥182.7 billion, down ¥120.5 billion, due to the recognition of impairment losses and other non-recurring items related to the Chemicals and Healthcare segments.」

    Although revenue and core operating profit increased, operating profit and profit for the year attributable to owners of the parent declined due to impairment losses and other charges.
  12. FY2023-Q3Lower nine-month profitAnnual report

    「Revenue was ¥3.4062 trillion, up ¥505.9 billion year on year. On the earnings side, core operating profit was ¥177.9 billion, down ¥41.0 billion; operating profit was ¥48.6 billion, down ¥169.6 billion, due to impairment losses and other charges related to the Chemicals and Healthcare segments recorded in non-recurring items; quarterly profit before tax was ¥39.2 billion, down ¥169.0 billion; and quarterly profit attributable to owners of the parent was ¥17.0 billion, down ¥105.1 billion.」

    In the nine-month consolidated period, revenue increased, while core operating profit, operating profit, quarterly profit before tax and quarterly profit attributable to owners of the parent declined year on year.
  13. FY2023-Q2Lower first-half profitAnnual report

    「Revenue was ¥2.2698 trillion, an increase of ¥384.7 billion year on year. Core operating profit was ¥122.6 billion, down ¥33.5 billion, operating profit was ¥118.4 billion, down ¥34.7 billion, profit before tax was ¥122.0 billion, down ¥25.2 billion, and profit for the quarter attributable to owners of the parent was ¥73.9 billion, down ¥11.3 billion.」

    Although revenue increased year on year, core operating profit, operating profit, quarterly profit before tax and quarterly profit attributable to owners of the parent declined.
  14. FY2023-Q1Decline in quarterly earningsAnnual report

    「Revenue was ¥1.1065 trillion, up ¥178.2 billion year on year. On the earnings side, core operating profit was ¥72.1 billion, down ¥16.6 billion, operating profit was ¥68.0 billion, down ¥19.0 billion, quarterly profit before tax was ¥75.1 billion, down ¥10.2 billion, and quarterly profit attributable to owners of the parent was ¥44.9 billion, down ¥5.0 billion.」

    Although revenue increased, core operating profit, operating profit, quarterly profit before tax and quarterly profit attributable to owners of the parent all declined year on year.
  15. FY2022Recovery in full-year performanceAnnual report

    「Revenue was ¥3.9769 trillion, an increase of ¥719.4 billion from the previous consolidated fiscal year. Core operating profit was ¥272.3 billion, up ¥97.6 billion, operating profit was ¥303.2 billion, up ¥255.7 billion, profit before tax was ¥290.4 billion, up ¥257.5 billion, and profit for the year attributable to owners of the parent was ¥177.2 billion, up ¥184.8 billion.」

    From lower profit and a loss attributable to owners of the parent in the previous year, FY2021 saw revenue and profit growth, with profit for the year attributable to owners of the parent recovering to ¥177.2 billion.
  16. FY2022-Q3Recovery in nine-month resultsAnnual report

    「Revenue was ¥2.9003 trillion, an increase of ¥544.9 billion year on year. Core operating profit was ¥218.9 billion, up ¥105.3 billion, operating profit was ¥218.2 billion, up ¥217.5 billion, profit before tax was ¥208.2 billion, up ¥221.0 billion, and profit for the quarter attributable to owners of the parent was ¥122.1 billion, up ¥169.9 billion.」

    Results recovered from the declining profit and loss trend through the previous year, with revenue and the key profit measures increasing substantially year on year for the nine-month cumulative period.
  17. FY2022-Q2Recovery in first-half resultsAnnual report

    「Under these circumstances, revenue was ¥1.8851 trillion, up ¥380.3 billion year on year. On the earnings side, core operating profit was ¥156.1 billion, up ¥101.5 billion, operating profit was ¥153.1 billion, up ¥181.2 billion, quarterly profit before tax was ¥147.2 billion, up ¥184.0 billion, and quarterly profit attributable to owners of the parent was ¥85.2 billion, up ¥134.9 billion.」

    Against a backdrop of recovering demand and rising market conditions, revenue and the key profit measures increased substantially year on year, recovering from a loss in the previous corresponding period to a profit.
  18. FY2022-Q1Quarterly Earnings RecoveryAnnual report

    「During the first quarter of the fiscal year ending March 2022 (1 April 2021 to 30 June 2021), the Group's business environment saw domestic and overseas demand trend toward recovery as economic activity in each country gradually normalized with the progress of vaccinations and other factors.」

    Against the declining profit trend through the previous year, core operating profit and other measures increased substantially year on year in the current first quarter as demand recovered.
  19. FY2021Deterioration in full-year resultsAnnual report

    「Under these circumstances, revenue was ¥3.2575 trillion, down ¥323.0 billion from the previous consolidated fiscal year. On the earnings side, core operating profit was ¥174.7 billion, down ¥20.1 billion, partly due to fixed-cost reductions; operating profit was ¥47.5 billion, down ¥96.8 billion, due to impairment losses and other charges related to the healthcare business recorded in non-recurring items; profit before tax was ¥32.9 billion, down ¥89.1 billion; and profit for the year attributable to owners of the parent was a loss of ¥7.6 billion, down ¥61.7 billion.」

    Profit declined for a second consecutive year, and profit for the year attributable to owners of the parent turned into a loss.
  20. FY2021-Q3Quarterly Earnings RecoveryAnnual report

    「In the third quarter of the current consolidated fiscal year (1 October 2020 to 31 December 2020), core operating profit increased by ¥8.8 billion, or 17.3%, to ¥59.0 billion compared with the same quarter of the previous year (1 October 2019 to 31 December 2019). Demand recovered, particularly for automotive applications, and core operating profit increased in all segments except healthcare.」

    Although the cumulative period saw lower profit and a loss, core operating profit in the current third quarter increased 17.3% year on year as demand recovered, particularly for automotive applications.
  21. FY2021-Q2Quarterly Performance DeterioratedAnnual report

    「Under these circumstances, revenue was ¥1.5048 trillion, down ¥322.9 billion year on year. On the earnings side, core operating profit was ¥54.6 billion, down ¥76.2 billion, while operating loss was ¥28.1 billion, down ¥158.7 billion, due to impairment losses and other charges related to the healthcare business recorded in non-recurring items.」

    In the six months ended 30 September 2020, revenue, core operating profit and operating profit declined substantially year on year, resulting in an operating loss.
  22. FY2021-Q1Quarterly Performance DeterioratedAnnual report

    「Under these circumstances, revenue was ¥722.7 billion, down ¥193.7 billion year on year. On the earnings side, core operating profit was ¥15.0 billion, down ¥55.1 billion, operating profit was ¥23.7 billion, down ¥46.2 billion, profit before tax was ¥20.4 billion, down ¥46.2 billion, and quarterly profit attributable to owners of the parent was ¥5.2 billion, down ¥32.6 billion.」

    The decline in profit since FY2018, when the company posted record-high profit, continued into the first quarter of FY2021, with revenue, core operating profit, operating profit and quarterly profit attributable to owners of the parent all declining year on year.
  23. FY2020Profit declined from the record highAnnual report

    「Revenue was ¥3.5805 trillion, down ¥259.8 billion from the previous consolidated fiscal year. On the earnings side, core operating profit was ¥194.8 billion, down ¥119.3 billion, while operating profit was ¥144.3 billion, down ¥150.5 billion, due to impairment losses and other charges related to the healthcare business recorded in non-recurring items.」

    After reaching a record high in the previous year, core operating profit and operating profit declined in the current year.
  24. FY2019Cited as achievedAnnual report

    「Core operating profit was ¥380.5 billion in the previous consolidated fiscal year, compared with ¥317.2 billion in the current consolidated fiscal year.」

    The previous year's record-high profit was cited as the comparison base, while core operating profit declined in the current year rather than setting a new record.
  25. FY2018AdvancedAnnual report

    「Amid generally favorable market conditions during the consolidated fiscal year, core operating profit was ¥380.5 billion, up ¥73.0 billion from the previous consolidated fiscal year, while profit for the year attributable to owners of the parent was ¥211.8 billion, up ¥55.5 billion. Both reached record highs.」

    The company stated that both core operating profit and profit for the year attributable to owners of the parent reached record highs.
  26. FY2016First statedAnnual report

    「The company worked to strengthen and raise its medium-term earnings base, achieved the operating profit target for the final year of the plan, and posted its highest-ever profit.」

    The company stated that it achieved the operating profit target in the final year of APTSIS 15 and posted its highest-ever profit.
Moved together

"Geopolitical, regulatory, infrastructure and personnel risks associated with overseas expansion" moved the same way as this thread, in the same document, in 3 of its 29 moves.

32★12
  1. ★This thread
  2. 1Geopolitical, regulatory, infrastructure and personnel risks associated with overseas expansion3×
  3. 2Results against APTSIS 15 financial targets2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for Mitsubishi Chemical Group yet. It last moved in the Governance of 2026-06-30: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.